EMEA-000901-PIP03-16-M02
Key facts
| Invented name |
Jakavi
|
| Active substance |
Ruxolitinib (phosphate)
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0172/2021
|
| PIP number |
EMEA-000901-PIP03-16-M02
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of acute graft-versus-host disease (aGvHD)
|
| Route(s) of administration |
|
| Contact for public enquiries |
Novartis Europharm Limited
Tel. +41 6132 41111 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|